6 курс / Кардиология / Хроническая_сердечная_недостаточность_1

Cardiology and the American Heart Association, Inc.- 55 p.

16.Adamopoulos S., Parissis J.T., Kremastinos D.T. A glossary of circulating cytokines in chronic heart failure // Europ. Heart. Failure.-2001.-V.3.- p.517-526.

17.AIRE: The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors in acute myocardial infarction with clinical evidence of heart failure//Lancet1993. -v. 342. - p. 821 -828.

18.Anker S.D., Ponikowski P.P., Clark A.L et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure // European Heart J.- 1999.-V.20.-P.683-693.

19.Anker S.D., Rauchhaus M. Heart failure as a metabolic prob lem//Europ. J. Heart Failure. - 1999. - v. 1. - p. 127 - 131.

20.Aukrust P., Ueland ., Lien E. etal. Cytokine network in con gestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy// Amer. J. Cardiol.- 1999.-V. 83.- p.376-382.

21.Benedict C.R., Johnstone D.E., Weiner D.H. et al. Relation of neurohormonal activation to clinical variables and degree of

ventricular dysfunction: a report from the registry of studies of left ventricular dysfunction//J. Amer. Coll. Cardiol.-1994.-v.23.- p.1410-1420.

22.Berry C, Clark A.L. Catabolism in chronic heart failure // Europ. J. Heart Failure.-2000.-v.21.-p.521-532.

23.Bonet S., August M.A., Arnau J.U. et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials//Arch.Intern.Med.-2000.-v. 160.- p.621-627.

24.BristowM.R., Hershberger RE., Port J.D. etal. -adrenergic pathways in nonfailing and failing human ventricular myocardi um//Circulation.- 1990.-V. 82.(Suppl I).-1 12-1 25.

25.Brater D.C. Diuretic theraphy// N. Eng.J.Med.- 1998.-V. 339.- p.387 - 395.

26.BroddeO-E. p1 -and P2 - adrenoreceptors in human heart: properties, function, and alterations in chronic heart failure . // Pharmacol. Rev.- 1991. - v.43. - p.202-242.

27.Burnier M., Brunner H.R. Angiotensin II receptor antagonists // Lancet.- 2000.-v.355.-p.637-645.

28.Cazeau S, Leclerc C, Lavergne N. et al. Effects of multisite biventricular pacing in patients with heart failure and intraven tricular conduction delay// N. Eng. J. Med.- 2001.-v. 344.- p.873 - 880.

29.Ceconi G., Feuerstein G. Oxidative stress links cytokine activation with apoptosis / In. Heart Failure: New Goals, New Guidelines. Ed.: Remme W.J. - SKB Publ., 1997.-p.4-6.

30.Cheng C.R, Onishi K., Onte N. et al. Functional effects of endogenous bradykinin in congestive heart failure //J.Amer.

Coll.Cardiol.- 1998.-V.31.-p. 1679-1686.

31. CIBIS-II Investigators and Committees. The cardiac insuffiency bisoprolol Study II (CIBIS-II): a randomised trial // Lancet.- 1999.-v.353.-p.9-13.

32.Clark A.L, Poole-Wilson P.A., Coats A.I.S. Exercise limitafion in chronic heart failure: the central role of the periphery // J/ Amer. Cardiol. - 1996. - v.28. - p. 1092-1102.

33.Cleland J.G.F., Witte K., Thackray S. Bradykinin and ventric ular function // Europ. Heart. J. -Suppl.- 2000.-v.2.-(Suppl H).- p.H20-H29.

34.Cohn J.N., Levine ., Olivari M.T. et al. Plasma norepineph rine as a guide to prognosis in patients with chronic congestive heart failure//N. Engl. J. Med. - 1984. -v. 311. - p. 819 - 823.

35.Cohen-Solal A. Role of aldosterone in heart failure. // Europ Heart. J. Suppl.- 2000. -v. 2., Suppl. A.-p. A 17 - A 20.

36.Colucci W.S. The sympathetic nervous system in congestive heart failure/In: Congestive Heart Failure. Eds. Hosenpud J.D., Greenberg B.H.- New York, Springer-Verlag.-1994.-p.126-135.

37.Comini L, Bachetti ., Angoletti L. etal. Induction of func tional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor - a//Europ. Heart J.-1999.-V.20.- p. 1503-1513.

38.Congestive Heart Failure. Pathophysiology, Diagnosis and Comprehensive Approach to Management/ Eds.: Hosenpud J.D., Creenberg B.H.- Springer-Verlag New York.-1994.- 769 p.

39.Cook S.A., Poole-Wilson PA. Cardiac myocyte apoptosis // Europ. Heart. J. -1999.-v.20.-p. 1619-1629.

40.Cowburn P.J., Cleland J.G., Coats A.J., Kimajda M. Risk stratification in chronic heart failure // Europ. Heart J. - 1998. - v. 19. - p. 696- 7 10.

41.Cowburn P.J., Cleland J.G F. Endothelin antagonists for chronic heart failure: do they have a role ? // Europ. Heart. J.- 2001 .-v. 19.- p.1772-1784.

42.Cowie M.R., W ood D.A., Coats A. et al. Survival of patienrs with new diagnosis of heart failure : a population based study // Heart.-2000.-v.83.-p.505-510.

43.Depre C, Davies P.J.L., Taegtmeyer H. Transcriptional adaptation of the heart to mechanical unloading // Amer. J.

Cardiol.- 1999.-vol.83.-p.58 H-63 H.

44.Ferguson D., Berg W., Roach P. et al. Effects of heart failure on baroreflex control of sympathetic neural activity // Amer.J.Cardiol.-1992.-v.69.-p.523-531.

45.Ferrari R., Bachetti ., Agnoletti L. et al. Endothelial function and dysfunction heart failure // Europ. Heart J.-1998.-v. 19 (Suppl.G), G41 - G47.

46.Feuerstein G.S., Puffolo R.R. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protec tion // Europ. Heart. J.- 1996.-V. 17, Suppl. : p. 24 - 29.

47.Feurestein G.S., Poste G., Ruffolo R.R. Carvedilol update III: rationale for use in congestive heart failure // Drugs of Today. - 1995.-V.31.-p.307-326

48.Francis G.S., Cohn J.N., Johnson G. et al. Plasma norepi nephrine, plasma renin activity and congestive heart failure. Relations of survival and the effects of therapy in V-He FT II. The V-He FT Cooperative Studies Group // Circulation.- 1993.- v.87 (Suppl XI): p. 140148.

49.Fruhwald F.M., Fahrleitner A., W atzinger N. etal. N-terminal proatrial natriuretic peptide correlates with systolic dysfunction and left ventricular filling pattern in patients with idiopathic dilat ed cardiomyopathy// Heart.- 1999.-v.82.- p.603-1109.

50.Gilbert E.M., Olsen S.L, Renlund D.G., Bristow M.R. Betaadrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy//Amer. J. Cardiol.-1993,- v.71. (Suppl C).-p.23c-29c.

51.Gilbert E.M., Olsen S.L, Renlund D.G., Bristow M.R. Betaadrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy//Amer. J. Cardiol.-1993.- V.71.-N9. - p. 23 -29 .

52.Grassi J., Seravalle G., Cattaneo B.U. et al. Sympathetic activation and loss of reflex sympathetic control in mild conges tive heart failure // Circulation.- 1995.- v.92.-p. 3206 - 3211.

53.Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the Diagnosis and Treatment of Chronic

Heart Failure, European Society of Cardiology: W.J.Remme and K.Swedberg (Co-Chairmen). // Europ. Heart J.-2001.-v.22.- p. 1527-1560.

54.Hartl W.H. Effects of kinins on glucose and protein metabo lism in vivo / In : The role of bradykinin in the cardiovascular action of the converting enzyme inhibitor ramipril. Eds Bonner G., Scholkens B.A., Chichester,, Media Medica.-1992.- p. 111-

55.Hornig ., Arakawa N., Drexler H. Effect of ACE inhibition on endotelial dysfunction in patients with chronic heart failure // Europ. Heart. J. - 1998.-v.19 (Suppl. G.) - G 48 - G 53.

56.Ikeda U., Shimada K. Nitric oxide and cardiac failure // Clin Cardiol.-1997.-v.20.-p. 837-841.

57.Katz A. Heart Failure. Pathophysiology, Molecular Biology and Clinical Management/ Philadephia, Lippincott Williams a. Wilkins, 2000.- 381 p.

58.Kendall M.J. Possible mechanisms of action in the positive effect of beta-blockers in heart failure // Heart.-1999.-v. 82, Suppl.lV: p. IV5-IV17.

59.Kupari M., Lindroos M., Jivanainen A.M. et al. Congestive heart failure in old age; prevalence, mechanismus and 4-year prognosis in the Helsinki Ageing Study//J.Int. Med. - 1997. - v.

241.- p. 387 - 394.

60.Levine T.B., Francis G.S., Goldsmith S. Activity of the sympa-

thetic nervous system and renin - angiotensin system assessed hormone levels and ther relationship to hemodynamic abnormalities in congestive heart failure // Amer. J. Cardiol. - 1992. -v. 49.-p. 16591666.

61. Lorell B.H. Role of angiotens'n AT1 and AT2 receptors in car diac hypertrophy and disease//Amer. J. Cardiol.- 1999.- vol.83.-p.48 H-52 H.

62.Luchner A., Borgeson D.D., Grantham J. etal. Relationship between left ventricular wall stress and ANP gene expression during the evolution of rapid ventricular pacing-induced heart failure in the dog //Europ.J. Heart Failure.- 2000.-V.2.- p.379-

63.Mark A.L. Sympathetic dysregulation in heart failure: mech anisms and therapy//Clin. Cardiol.- 1995. - v.18 (Suppl I).- p. I3 -18.

64.Massie B.M., Abdalla I. Heart failure in patients with pre served left ventricular systolic function: do digitalis glycosides

have a role ? // Progr. Cardiovasc. Dis.- 1998.-V. 40.- p.357 - 369.

65.Me Murray J., Cohen-Solal A., Dietz R. et al. Practical rec ommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure : putting guidelines into practice // Europ.J.Heart Failure.-2001 .-v.3.-p.495-502.

66.MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) // Lancet.- 1999.-v.353.-p.2001-2007.

67.Metra M., Giubbini R., Nodari S. et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol // Circulation, -2000.-v.102.-

p.546-551.

68.Mosterd A., Hoes A.W., de Bruyne M. C, et al. Prevalence of heart failure left ventricular dysfunction in the general popula tion. The Rotterdam Study. // Europ. Heart J. - 1999. - v. 20. - p. 447 - 455.

69.Munger M.A., Furniss S.M. Angiotensin II receptor blockers: novel therapy for heart failure // Pharmacotherapy Card. Mass. - 1996.- v. 16 (Part 2). 59 S - 68 S.

70.Neubauer S. High-energy phospate metabolism in normal, hypertrophied and failing human myocardium// Heart Failure Rev. - 1999. v.4. - p.269-280.

71.Nishikimi T. Adrenomedullin in cardiovascular disease // Adv. Pharmacol.- 1998.-v. 42.- p.599-603.

72.Nogele H., Bohlann M., Eck U. et al. Combination therapy with carvedilol and amiodarone in patients with severe heart fail ure // Europ. J.Heart Failure.-v.2.-p.71-79.

73.O'Connel J.B., BristowM.R. Economic impact of heart fail ure in the United States: time for a different approach //J. Heart Lung Transplant. -1993. -v. 13. -S 107 - S 112.

74.Olivetti G., Abbi R., Quaini F. Apoptosis in the failing human heart//N. Engl. J. Med.-1997. - v.336. - p. 1131-1141.

75.100 years of the renin-angiotensin system. / Eds. Nicholls M.G., Brunner H.R., Ikram H. Merk.Co Inc., Whitehouse Station, N.J., USA, 1998.-180p.

76.Otterstad J.E., Froeland G., Sutton M., Holme I. Accuracy and reproducibility of biplane two-dimensional echocardio graphy measurements of left ventricular dimensions and func tion//Europ. Heart J.- 1997 .-v.18.-p.507-513.

77.Packer M., BristowM.R., Cohn J.N. etal. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group // N/ Engl. J. Med.- 1996.-v.334.-p. 1349-1355.

78.Packer M., Coats A.I.S., Fowler M.B. et al. for the Carvedilol Prospective Randomise Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure // N.Engl. J. Med.- 2001.-v.344.-p.1651-1658.

79.Parchure N.A., Kaski J. . Oxidant stress (reactive oxygen species) and cardiovascular disease (part I) // Europ. Cardiologist J.-1998.-V.3.-N 72-12/11.

80.Paulus W.J. How are cytokines activated in heart failure ? // Europ. Heart Failure.-1999.-v.L-p.309-312.

81.Pausset F, Isnard R., Lechat P. et al. Prognostic value of plasmaendothelin -1 in patients with chronic heart failure // Europ. Heart J.-1997.-V.18.- p.254-258.

82.Pausset F, Masson F, Chavirovskaia O. et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure // Europ. Heart. J. -2000.- v.21.-p.1009-1014.

83.Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of capto pril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators // N.Engl. J. Med.- 1992,-v.327.-p.669-677.

84.Pitt ., Poole-Wilson P.A., Segal R. etal. on behalf of the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: ran domised trial - the Losartan Heart Failure Survival Study ELITE II // Lancet.- 2000.-v.355.-p. 1582-1587.

85.23. Pitt ., Segal R., Martinez F.A., et al. on behalf of ELITE Study Investigators. Randomised trial of losartan versus capto pril in patients over 65 with heart failure (Evaluation of Losartan in Elderly Study ELITE)//Lancet.- 1997.-v.349.-p.747-752.

86.Pitt ., Zannad R, Remme W.J. et al. The effect of spirono lactone on morbidity and mortality in patients with severe heart failure// Randomized Aldactone Evaluation Study Investigators //N.Engl. J. Med.- 1999.-v.341.-p.709-717.

87.Ponikowsky P., Banasiak W. Chemosensitivity in chronic heart failure //Heart Failure Monitor. -2001. - v.1.- N4. - p. 126 -131

88.Rihal C.S., Davis V.B., Kennedy J.W., Gersh B.J. The utility of clinical, echocardiographic and roentgenographic variables in the prediction of lef ventricular function // Amer. J. Cardiol. - 1995.-v.75.-p.220-223.

89.Rose E., Gellijns A.C., Moskowitz A.J. et al. for the REMATCH study group. Long-term use of a left ventricular assist device for end-stage heart failure // N. Eng. J. Med.- 2001 .-v.

345.-p. 14351443.

90.Rosenzweig A., Seidman Atrial natriuretic factor and related peptide hormone// Ann. rev. Biochem.. -1991.-v.60.- p.229-255.

91.Rostagno C, Galanti G., Felici M. et al. Prognostic value of baroreflex sensitivity assessed by phase IV of Valsalva maneuvre in patients with mild-to-moderate heart failure // Europ. J. Heart Failure.-2000.-v.2.-p,41 -45.

92.Rouleau J.J.L., Pfeffer M.A., Stewart D.J. et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised tril // Laancet.-2000.-v.356.-p.615-620.

93.Sabbah H.N., Stanley W.C. Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure // Europ. J. Heart. Failure. - 2002.-V.4. - p.3 - 6.

94.Sabbah H. The cellular and physiologic effects of betablockers in heart failure//Clin.Cardiol.-1999.-v. 22, Suppl.5: p. V16-V20.

95.Saraste A., Pulkki K., Kallajoki M.et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation // Eur.J.CIin. Invest.-1999.-v. 29 (5).-p.380-386.

96.Sasayama S., Matsumori A., Kihara G. et al. New insights into the pathophysiological role for cytokines in heart failure // Cardiovasc. Res. - 1999.-v.42.- p.557-564.

97.Singh S.N. Congestive heart failure arrhythmias: therapeutic modalities//J. Cardiovasc-1997,-v. 8 - p. 88-97.

98.Sleight P. The renin-angiotensin system: a review of trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blocking agents // Europ. Heart J. Suppl. -2002.- v.4. (Suppl. 4).- p. A53-A57.

99.Spinale F.G., Coker M.L., Bond B.R., Zellner J.L Myocardial matrix degradation and metalloproteinase activation in the fail ing: heart a potential therapeutic target // Cardiovasc. Res. - 2000.-V.46.-P.225-238.

100.Swynghedauw ., RapaportL., Schwartz . Heart failure as a disease of adaptation / In : Cardiac hypertrophy and failure. Ed. Swynghedauw B. INSERM / John Libbey Eurotext. - London - Paris. - 1990. - p. 679-686.

101.Swynghedauw B. Myocardial effects of nitric oxide: what should the clinician remember? // Europ. Cardiologist J.-2000.- v.-N 2.-10.01.

102.Talwar S., Squire I. ., Davies J.E. et al. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population // Europ.Heart.J. - 1999.-v.20.- p.1736-1744.

103.The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: Results of the

Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) // N.Engl. J. Med. - 1987. - v. 316 - p. 1429 - 1435.

104.The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure // N. Eng. J.Med. - 1997.- v. 336. - p. 525 - 533.

105.The SOLVD investigators. Effect of enalapril on survival in patients with reduced ejection fraction and congestive heart fail ure. // N.Engl. J. Med. - 1991. - v. 325 - p. 293 - 302.

106.The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients

with reduced left ventricular ejection fraction // N.Engl. J. Med. - 1992.-v. 327-p. 685-691.

107. Torre-Amrione J., Volletich M.T., Farmer J.A. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications// Drugs. -2000.-v.59.-p.745-751.

108.TRACE: Torp-Pe^tersen C, Kober L, Carlsen J. Angiotensin - convertiong enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study //Amer Heart J. -1996. -

v.132.-p. 235-243.

109.Tsumamoto T, Wada A., Maeda K. et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction // Europ.Heart.J. - 1999.-V.20.-P.1799-1807.

110.Tyagi S.C., Bheemanathini VS., Mandi D. Role of extracel lular matrix metalloproteinases in cardiac remodeling // Heart Failure Review.-1996.-v.L-p.73-80.

111.Ventricular remodeling and heart failure / Eds. Cohn. J.N., Ferrari R., Sparpe N. - London, SKB Publ., 1998. - p. 29 p.

112.Wei ., Lerman A.L, Rodeheffer R.J. etal. Endothelin in | human congestive heart failure//Circulation.-1994.-v.89.- p.1580-1586.

113.Yamasaki N. Role of renin-angiotensin system in cardiac hypertrophy//Amer. J. Cardiol.- 1999.-vol.83.-p.53 H-57 H.

114.Yoshikawa ., Port J.D., Asano . et al. Cardiac adrener gic receptor effects of carvedilol // Europ. Heart J. -1996. - v.17| (Suppl.B). -p. 8-16.